Mark Bagnall
CFO
Mark is CFO at Akiri, bringing his biotech expertise in rare and metabolic diseases and in clinical diagnostics. Previously, Mark co-founded Naia Pharmaceuticals, where he developed two new pharmaceutical development companies targeting both mature and emerging markets. He has served as CFO and COO of several public and private biotech companies. Mark is a member of the Board of Directors of medical diagnostic company Ativa Medical, Inc., and Chairman of the Board of infectious disease diagnostics company XCR Dx. As President and CEO at Genturadx, Mark restructured and internationally relocated the organization, growing the team by 900 percent before acquisition. He earned his BS in Finance from UC Berkeley’s Walter A. Haas School of Business.
相关公司信息
你可能感兴趣Recommend
-
数字货币专题2021-03-17
-
数字货币专题2020-08-29
-
数字货币专题2020-09-29
-
数字货币专题2020-10-09
-
数字货币专题2020-12-27
-
数字货币专题2021-01-08
-
数字货币专题2023-08-08
-
区块链专题2020-07-31
